Phathom Pharmaceuticals Inc [PHAT] stock is trading at $4.84, up 9.75%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PHAT shares have gain 10.00% over the last week, with a monthly amount drifted -13.88%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Phathom Pharmaceuticals Inc [NASDAQ: PHAT] stock has seen the most recent analyst activity on February 14, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $23. Previously, Stifel started tracking the stock with Buy rating on May 03, 2024, and set its price target to $24. On January 05, 2024, Needham reiterated its Buy rating and revised its price target to $26 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $28 on August 09, 2023. Evercore ISI upgraded its rating to a Outperform. Craig Hallum started tracking with a Buy rating for this stock on March 13, 2023, and assigned it a price target of $21. In a note dated October 21, 2022, Jefferies initiated an Buy rating and provided a target price of $16 on this stock.
Phathom Pharmaceuticals Inc [PHAT] stock has fluctuated between $4.07 and $19.71 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Phathom Pharmaceuticals Inc [NASDAQ: PHAT] shares were valued at $4.84 at the most recent close of the market. An investor can expect a potential return of 271.9% based on the average PHAT price forecast.
Analyzing the PHAT fundamentals
Phathom Pharmaceuticals Inc [NASDAQ:PHAT] reported sales of 55.25M for the trailing twelve months, which represents a growth of 4249.56%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -5.02%, Pretax Profit Margin comes in at -6.05%, and Net Profit Margin reading is -6.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.88, Equity is 1.62 and Total Capital is -0.95. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.53 points at the first support level, and at 4.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.02, and for the 2nd resistance point, it is at 5.20.
Ratios To Look Out For
For context, Phathom Pharmaceuticals Inc’s Current Ratio is 4.20. Also, the Quick Ratio is 4.16, while the Cash Ratio stands at 3.47. Considering the valuation of this stock, the price to sales ratio is 6.10.
Transactions by insiders
Recent insider trading involved Parikh Asit, Director, that happened on Mar 13 ’25 when 10000.0 shares were purchased. CFO and CBO, Henderson Molly completed a deal on Jan 21 ’25 to sell 6583.0 shares. Meanwhile, Chief Operating Officer Nabulsi Azmi sold 7886.0 shares on Jan 21 ’25.
